Global Health Limited provides digital health solutions for the healthcare sector in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.34|
|52 Week High||AU$0.32|
|52 Week Low||AU$0.79|
|1 Month Change||-15.85%|
|3 Month Change||-28.13%|
|1 Year Change||-4.17%|
|3 Year Change||72.50%|
|5 Year Change||-27.37%|
|Change since IPO||-94.52%|
Recent News & Updates
What Can We Conclude About Global Health's (ASX:GLH) CEO Pay?
This article will reflect on the compensation paid to Alumootil Cherian who has served as CEO of Global Health Limited...
|GLH||AU Healthcare Services||AU Market|
Return vs Industry: GLH underperformed the Australian Healthcare Services industry which returned 46.7% over the past year.
Return vs Market: GLH underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: GLH is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: GLH's weekly volatility (11%) has been stable over the past year.
About the Company
Global Health Limited provides digital health solutions for the healthcare sector in Australia. It provides mental health software for psychologists and psychiatrists; and integrated software solutions for various areas of community health and human services, including drug and alcohol, disability, dental, post-acute care, home and community care, mental health services, and community rehabilitation, as well as offers software solutions for home care and aged care, consumer engagement form, general practice, and pharmacy. The company’s products include MasterCare EMR, an Electronic Medical Record; MasterCare + providers flexibility and accessibility managing their services and processes from anywhere; MasterCare PAS, a patient administration system; PrimaryClinic, a medical and practice software for general practitioners, specialists, and allied health practitioners; ReferralNet, a secure messaging exchange; LifeCard, a personal health record.
Global Health Fundamentals Summary
|GLH fundamental statistics|
Is GLH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GLH income statement (TTM)|
|Cost of Revenue||AU$5.60m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0086|
|Net Profit Margin||-6.94%|
How did GLH perform over the long term?See historical performance and comparison
Is Global Health undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GLH (A$0.35) is trading below our estimate of fair value (A$0.86)
Significantly Below Fair Value: GLH is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GLH is unprofitable, so we can't compare its PE Ratio to the Global Healthcare Services industry average.
PE vs Market: GLH is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GLH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GLH is overvalued based on its PB Ratio (4.8x) compared to the AU Healthcare Services industry average (3.8x).
How is Global Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Global Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Global Health performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GLH is currently unprofitable.
Growing Profit Margin: GLH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GLH is unprofitable, and losses have increased over the past 5 years at a rate of 25.3% per year.
Accelerating Growth: Unable to compare GLH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GLH is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (39.5%).
Return on Equity
High ROE: GLH has a negative Return on Equity (-12.08%), as it is currently unprofitable.
How is Global Health's financial position?
Financial Position Analysis
Short Term Liabilities: GLH's short term assets (A$5.5M) exceed its short term liabilities (A$4.7M).
Long Term Liabilities: GLH's short term assets (A$5.5M) exceed its long term liabilities (A$339.9K).
Debt to Equity History and Analysis
Debt Level: GLH's debt to equity ratio (7.4%) is considered satisfactory.
Reducing Debt: GLH's debt to equity ratio has reduced from 47.2% to 7.4% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable GLH has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: GLH is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 4.8% per year.
What is Global Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GLH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GLH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GLH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GLH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GLH's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Michael Davies serves as the Chief Executive Officer at Global Health Limited since July 1, 2021. He has extensive background leading technology adoption, driving sales and go-to-market strategies in t...
Experienced Management: GLH's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Experienced Board: GLH's board of directors are considered experienced (8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 34.5%.
Global Health Limited's employee growth, exchange listings and data sources
- Name: Global Health Limited
- Ticker: GLH
- Exchange: ASX
- Founded: 1985
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: AU$19.530m
- Shares outstanding: 56.61m
- Website: https://www.global-health.com
Number of Employees
- Global Health Limited
- 696 Bourke Street
- Level 2
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 15:14|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.